Investigating the Effect of Standardized Olive Extract on Bone Turnover Markers in Postmenopausal Women
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00789425|
Recruitment Status : Completed
First Posted : November 11, 2008
Last Update Posted : July 13, 2017
|Condition or disease||Intervention/treatment||Phase|
|Osteoporosis Osteopenia||Dietary Supplement: Standardized Extract of Olive Polyphenols Dietary Supplement: Placebo||Phase 2|
Apart from estrogen deficiency, the early postmenopausal period is also characterised by an increasing inflammatory and oxidant status, which further contributes to the development of osteoporosis/osteopenia. The link between systemic inflammation and osteoporosis has only been established recently as it was found that higher circulating hsCRP levels are associated with lower bone mineral density in both healthy pre- and postmenopausal women. Furthermore, it was already known for a long time that one of the most important cytokines implicated in the pathogenesis of various metabolic bone diseases, including postmenopausal osteoporosis, is interleukin (IL)-6, which is produced by osteoblasts, monocytes and T-cells.
Olive oil is the principle fat source of the traditional Mediterranean diet, a diet that has been associated with a low incidence of some diseases, including coronary heart disease and osteoporosis. In addition to the main ingredient (ie. oleic acid) extra virgin olive oil also contains phenolic compounds, such as oleuropein- and ligstroside-aglycones and their derivatives. They are formed in olives by enzymatic removal of glucose from the polar parent compound oleuropein-glycoside. A Mediterranean diet rich in olive oil supplies 10 - 20 mg of phenols per day.
The main metabolic attribute of oleuropein is that it exerts both antioxidant and anti-inflammatory activity by lowering the levels of proinflammatory cytokines like IL-1, IL-6 or TNF-alpha. By inhibiting osteoclast activity, this may result in lowering the rate of bone resorption and, at least in part, protect against osteoporosis development.
Formulated as a capsule it is expected that the compliance and tolerability will be improved compared to the liquid administration. The present study is designed to investigate the effect of 250 mg of a standardized extract of olive polyphenols per day on bone loss in postmenopausal women with decreased bone mass (osteopenia) .
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||64 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||A Randomised, Double Blind, Parallel Group, 12-month Comparison of a Standardized Olive Extract With Placebo in Postmenopausal Women With Decreased Bone Mineral Density|
|Study Start Date :||September 2008|
|Actual Primary Completion Date :||March 2010|
|Actual Study Completion Date :||March 2010|
Active Comparator: 1
a standardized extract of olive polyphenols at 250 mg per day + 1000 mg of calcium per day.
Dietary Supplement: Standardized Extract of Olive Polyphenols
Dietary supplement containing 250 mg of a standardized extract of olive polyphenols per day in 1 capsule.
A supplement with 1000 mg calcium per day will be supplied together with the active treatment.
Placebo Comparator: 2
Placebo (starch) + 1000 mg of calcium per day.
Dietary Supplement: Placebo
Placebo (starch). A supplement with 1000 mg calcium per day will be supplied together with the active treatment.
- Serum levels of Osteocalcin and CTX will be used as bone turnover markers [ Time Frame: 0, 3, 6, and 12 months ]
- Bone mineral density as measured by DEXA in lumbar spine and total hip [ Time Frame: 0 and 12 months ]
- hs-CRP and IL-6 in serum as inflammation markers [ Time Frame: 0, 6, and 12 months ]
- ORAC values in serum as oxidative stress marker [ Time Frame: 0, 6, and 12 months ]
- Total cholesterol, HDL-C, LDL-C, triglycerides in serum as CVD-risk markers. [ Time Frame: 0, 6, and 12 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00789425
|Osteoporosis Outpatient of the Institute of Agricultural Medicine|
|Lublin, Poland, 20-950|
|Principal Investigator:||Rafal Filip, MD PhD||Institute of Agricultural Medicine|